{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"description":"Time to response is measured from the start of treatment until the first date that criteria are met for complete response or partial response.","groups":[{"description":"Dasatinib will be administered continuously at an oral dose of 70 mg BID on Days 1-28 of each 28 day cycle.\n\nIn patients with stable disease after 8 weeks on therapy the dasatinib will be increased to 100 mg BID on Days 1-28 on each 28 day cycle.","id":"OG000","title":"Dasatinib"}],"paramType":"NUMBER","populationDescription":"Only one patient achieved a partial response.","reportingStatus":"POSTED","timeFrame":"Completion of treatment (median duration of therapy was 51 days)","title":"Time to Response","type":"SECONDARY","unitOfMeasure":"cycles"}